BeiGene (HKG:6160, SHA:688235) swung to a net loss of $121.4 million in the third quarter from a profit of $215.4 million in the year-ago period.
The drugmaker incurred a loss per share of $0.09, reversing earnings per share of $0.15 in the previous year, according to a Wednesday filing with the Hong Kong Exchange.
Total revenue jumped to $1 billion from $781.3 million a year earlier, driven by growth in BRUKINSA product sales in the US and Europe.
Shares slid 3% in Hong Kong during Wednesday's morning trading.
Price (HKD): $116.90, Change: $-4.9, Percent Change: -4.02%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments